U.S., May 7 -- ClinicalTrials.gov registry received information related to the study (NCT06959537) titled 'A Phase Ib/II Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC)' on April 28.
Brief Summary: The goal of this clinical research study is to find the best dose of the drugs cyclophosphamide and axatilimab that can be given in combination with the standard dose of retifanlimab to patients with metastatic TNBC.
Study Start Date: Oct. 01, 2025
Study Type: INTERVENTIONAL
Condition:
Breast Cancer
Intervention:
DRUG: Cyclophosphamide
Given by mouth
DRUG: Axatilimab (SNDX-6352)
Given by IV
DRUG: Retifanlim...